Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 First-dose idarubicin cardiomyopathy: a case of new heart failure after induction chemotherapy for acute myeloid leukaemia.

Literature DB >> 31101747

First-dose idarubicin cardiomyopathy: a case of new heart failure after induction chemotherapy for acute myeloid leukaemia.

Zarir Ahmed¹, Elizabeth Davaro², Jacqueline Batanian², Nilesh Verma³.

Abstract

Anthracyclines are an effective chemotherapy agent. However, very few cases of idarubicin-induced cardiomyopathy exist. Herein, we describe a case of first-dose idarubicin-related acute heart failure in a woman with a history of myelodysplastic syndrome converted to acute myeloid leukaemia. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities: Chemical Disease Species

Keywords: cardiovascular system; chemotherapy; haematology (incl blood transfusion); heart failure

Mesh：

Substances：

Year: 2019 PMID： 31101747 PMCID： PMC6536188 DOI： 10.1136/bcr-2018-228149

Source DB: PubMed Journal: BMJ Case Rep ISSN： 1757-790X

Keyword Cloud
References

13 in total

1. Anthracycline cardiotoxicity: a new paradigm for an old classic.

Authors: John D Groarke; Anju Nohria
Journal: Circulation Date: 2015-05-06 Impact factor: 29.690

Review 2. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

Authors: Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos S Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake
Journal: Circulation Date: 2017-04-28 Impact factor: 29.690

Review 3. Anthracycline-Induced Cardiomyopathy in Adults.

Authors: Timothy C Tan; Tomas G Neilan; Sanjeev Francis; Juan Carlos Plana; Marielle Scherrer-Crosbie
Journal: Compr Physiol Date: 2015-07-01 Impact factor: 9.090

4. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.

Authors: Daniela Cardinale; Alessandro Colombo; Giulia Bacchiani; Ines Tedeschi; Carlo A Meroni; Fabrizio Veglia; Maurizio Civelli; Giuseppina Lamantia; Nicola Colombo; Giuseppe Curigliano; Cesare Fiorentini; Carlo M Cipolla
Journal: Circulation Date: 2015-05-06 Impact factor: 29.690

5. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.

Authors: Daniela Cardinale; Alessandro Colombo; Giuseppina Lamantia; Nicola Colombo; Maurizio Civelli; Gaia De Giacomi; Mara Rubino; Fabrizio Veglia; Cesare Fiorentini; Carlo M Cipolla
Journal: J Am Coll Cardiol Date: 2010-01-19 Impact factor: 24.094

6. Protective effects of carvedilol against anthracycline-induced cardiomyopathy.

Authors: Nihat Kalay; Emrullah Basar; Ibrahim Ozdogru; Ozlem Er; Yakup Cetinkaya; Ali Dogan; Tugrul Inanc; Abdurrahman Oguzhan; Namik Kemal Eryol; Ramazan Topsakal; Ali Ergin
Journal: J Am Coll Cardiol Date: 2006-11-09 Impact factor: 24.094

7. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies).

Authors: Xavier Bosch; Montserrat Rovira; Marta Sitges; Ariadna Domènech; José T Ortiz-Pérez; Teresa M de Caralt; Manuel Morales-Ruiz; Rosario J Perea; Mariano Monzó; Jordi Esteve
Journal: J Am Coll Cardiol Date: 2013-04-10 Impact factor: 24.094